Journal of Vaccine Research 2024, Vol.14, No.5, 255-268 http://medscipublisher.com/index.php/jvr 268 HER2-expressing breast tumors, Journal of Immunology, 211(2): 219-228. https://doi.org/10.4049/jimmunol.2300077 Vreeland T., Clifton G., Sears A., Hale D., Patil R., Clive K., Holmes J., Mittendorf E., Ponniah S., and Peoples G., 2011, P1-13-02: long-term clinical benefit of adjuvant breast cancer vaccine: 5-year efficacy of E75 with multiple booster inoculations, Cancer Research, 71(24_Suppl): P1-13-02. https://doi.org/10.1158/0008-5472.SABCS11-P1-13-02 Wang T., 2024, The application prospects of immunomodulators in cancer treatment, Cancer Genetics and Epigenetics, 12(1): 1-7. https://doi.org/10.5376/cge.2024.12.0001 Wei Q., and Taskén K., 2022, Immunoregulatory signal networks and tumor immune evasion mechanisms: Insights into therapeutic targets and agents in clinical development, The Biochemical Journal, 479(20): 2219-2260. https://doi.org/10.1042/BCJ20210233 Wolpoe M., Lutz E., Ercolini A., Murata S., Ivie S., Garrett E., Emens L., Jaffee E., and Reilly R., 2003, HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in HER-2/neu-transgenic mice, The Journal of Immunology, 171(4): 2161-2169. https://doi.org/10.4049/jimmunol.171.4.2161 Zhao J., Chen Y., Ding Z., and Liu J., 2019, Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment, Frontiers in Pharmacology, 10: 1184. https://doi.org/10.3389/fphar.2019.01184 Zhao J., Chen Y., Ding Z., and Liu J., 2019, Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment, Frontiers in Pharmacology, 10: 1184. https://doi.org/10.3389/fimmu.2022.1022808 Zhou J.Y., 2024, The Application of genomics in personalized cancer therapy, Cancer Genetics and Epigenetics, 12(1): 66-74. https://doi.org/10.5376/cge.2024.12.0009
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==